Congress Materials

RELISTOR®

(methylnaltrexone bromide) 8 mg/12 mg subcutaneous injection

Subcutaneous injection

Society of Hospital Medicine (SHM) 2022—April 7–10, 2022, Nashville, TN

Approved opioid-induced constipation medication use in emergency department patients with opioid-induced constipation

Peacock WF, et al.

Efficacy of methylnaltrexone in patients with advanced illness and opioid induced-constipation refractory to conventional laxatives: impact of baseline laxative use

Sayuk G, et al.

Attenuation of adverse events over 7 doses in methylnaltrexone-treated patients with opioid-induced constipation and severe medical illness

Sayuk G, et al.

Society of Critical Care Medicine (SCCM) Critical Care Congress 2022—February 6–9, 2022, San Juan, Puerto Rico

Naloxone versus methylnaltrexone for opioid-induced constipation in critically ill patients

Habeeb E, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2021—October 22–27, 2021, Las Vegas, NV

A pooled analysis of the efficacy and safety of methylnaltrexone for opioid-induced constipation in patients with severe medical illness: the impact of baseline opioid equivalent dose

Sayuk GS, et al.

American Society for Pain Management Nursing (ASPMN) 2021—September 29–October 2, 2021, San Antonio, TX

Repeat dosing with subcutaneous methylnaltrexone: a pooled analysis in patients with and without cancer

Shah E, et al.

American Neurogastroenterology and Motility Society (ANMS) Annual Scientific Meeting 2021—August 13–15, 2021, Boston, MA

SC methylnaltrexone in patients with advanced illness and OIC: the impact of baseline laxative use

Yu QT, et al.

Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO) Annual Meeting on Supportive Care in Cancer—June 24–26, 2021, Virtual

Rescue-free laxation response with methylnaltrexone treatment in cancer patients with opioid-induced constipation: the impact of baseline ECOG status

Boniol S, et al.

Society of Hospital Medicine (SHM) 2021—May 3–7, 2021, Virtual

Subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation and the impact of baseline osmotic and stimulant laxative use

Yu Q, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2020—October 23–28, 2020, Virtual

Subcutaneous methylnaltrexone in cancer and non-cancer patients for rapid relief of opioid-induced constipation

Shah ED, et al.

PAINWeek 2020—September 11–13, 2020, Virtual

Cumulative laxation response with methylnaltrexone: implications for hospitalized patients with advanced illness and opioid-induced constipation

Farchadi D, et al.

Society of Hospital Medicine (SHM) 2020—August 11–31, 2020, Virtual

Cumulative laxation response with methylnaltrexone: implications for hospitalized patients with advanced illness and opioid-induced constipation [Encore]

Farchadi D, et al.

Digestive Disease Week (DDW) 2020—May 2–5, 2020, Virtual

Cumulative laxation response with methylnaltrexone: implications for hospitalized patients with advanced illness and opioid-induced constipation [Encore]

Farchadi D, et al.

Attrition of methylnaltrexone treatment-emergent adverse events in patients with chronic noncancer pain and opioid-induced constipation [Encore]

Mehta N, et al.

4th Meeting of the Federation of Neurogastroenterology and Motility—March 25–28, 2020, Adelaide, Australia

PAMORAs result in clinically significant improvement in spontaneous and complete spontaneous bowel movements with low risk of side effects in patients with opioid induced constipation: systematic review and meta-analysis

Vijayvargiya P, et al.

American Academy of Hospice and Palliative Medicine (AAHPM): State of the Science in Hospice and Palliative Care 2020—March 20–22, 2020, Meeting Cancelled

Prevention and treatment of chronic and opioid-induced constipation in patients with cancer: a systematic review and meta-analysis

Ginex P, et al.

PAINWeek 2019—September 3–7, 2019, Las Vegas, NV

Attrition of treatment-emergent adverse events by methylnaltrexone in patients with chronic noncancer pain and opioid-induced constipation

Mehta N, et al.

Treatment with methylnaltrexone in patients with opioid-induced constipation with or without active cancer: effects of the initial dose based on 3 pooled clinical studies

Chamberlain B, et al.

Digestive Disease Week (DDW) 2019—May 18–21, 2019, San Diego, CA

The influence of age on central nervous system effects of methylnaltrexone in patients with opioid-induced constipation: a pooled analysis of 4 clinical trials

Liao S, et al.

Efficacy variables in cancer versus noncancer patients treated with methylnaltrexone or placebo: an analysis of two placebo-controlled studies

Chamberlain BH, et al.

Society of Hospital Medicine (SHM) 2019—March 24–27, 2019, National Harbor, MD

Treatment with methylnaltrexone in patients with opioid-induced constipation with or without active cancer

Chamberlain B, et al.

PAINWeek 2018—September 4–8, 2018, Las Vegas, NV

Methylnaltrexone for the relief of constipation due to chronic opioid therapy in advanced illness patients with and without active cancer

Chamberlain B, et al.

International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2017—October 15–18, 2017, Yokohama, Japan

Effectiveness of methylnaltrexone bromide in opioid-induced constipation in advanced NSCLC patients

Dimitroulis I, et al.

American College of Gastroenterology (ACG) Annual Scientific Meeting 2017—October 13–18, 2017, Orlando, FL

Effectiveness of various treatment agents for opioid-induced constipation: a meta-analysis

Saleem R, et al.

American Pain Society (APS) Annual Scientific Meeting 2017—May 17–20, 2017, Pittsburgh, PA

Oral methylnaltrexone for adults with chronic noncancer pain and opioid-induced constipation (OIC): timing and characterization of clinical symptoms do not suggest opioid withdrawal with daily treatment

Rauck R, et al.

Digestive Disease Week (DDW) 2017—May 6–9, 2017, Chicago, IL

Use of methylnaltrexone in cancer patients with peritoneal carcinomatosis

Nelson KK, et al.

PAINWeek 2016—September 6–10, 2016, Las Vegas, NV

Peripherally acting mu-opioid receptor antagonists (PAMORAs) for constipation associated with chronic opioid therapy

Pergolizzi JV, et al.

American Pain Society (APS) Annual Scientific Meeting 2015—May 13–16, 2015, Palm Springs, CA

Analysis of opioid-mediated analgesia in studies with methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain

Webster L, et al.

Society of Hospital Medicine (SHM) 2015—March 29–April 1, 2015, National Harbor, MD

Efficacy and safety of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain: a placebo crossover analysis  [Encore]

Viscusi ER, et al.

Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension

Bull J, et al.

American Pain Society (APS) Annual Scientific Meeting 2014—April 30–May 3, 2014, Tampa, FL

Efficacy and safety of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain: a placebo crossover analysis

Viscusi E, et al.

American Pain Society (APS) Annual Scientific Meeting 2013—May 8–11, 2013, New Orleans, LA

Efficacy and safety of subcutaneous methylnaltrexone in advanced illness patients with opioid-induced constipation: a responder analysis

Nalamachu S, et al.

Effect of subcutaneous methylnaltrexone on patient-reported outcomes in advanced illness patients with opioid-induced constipation

Peppin J, et al.

Neurogastroenterology and Motility 2011—September 16–18, 2011, St. Louis, MO

Subcutaneous methylnaltrexone provides long-term laxation in patients with chronic non-malignant pain and opioid-induced constipation  [abstract 153; page 44]

Webster LR, et al.

View product- and therapeutic area—related publications appearing in peer-reviewed journals.

Search

*Required field.

Select a product*

Select

Select a therapeutic area*

Select

Enter keyword(s)